Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Neurocrine Bio. (NBIX) PT Raised to $100 at H.C. Wainwright on Positive Survey Data
February 16, 2017 7:47 AM ESTHC Wainwright and Co. analyst Andrew Fein reiterates Buy rating and raises price target on Neurocrine Biosciences (NASDAQ: NBIX) to $100 (from $80), suggesting the company's shares are undervalued by nearly 60%, as proprietary physician surveys help identify the proper value post Opicapone deal.
Fein writes, "Correcting the value proposition surrounding opicapone. In our view, last week's... More
Needham & Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX) Ahead of 2017 Catalyst
February 15, 2017 7:58 AM ESTNeedham & Company analyst Alan Carr reiterates Buy and $62 price target on Neurocrine Biosciences (NASDAQ: NBIX), as the company remains focused on upcoming Ingrezza launch and Phase 2 pediatric Tourette Syndrome data due May 2017.
Carr comments, "Company continues to prepare for Ingrezza launch ahead of... More
Baird Reiterates Outperform Rating and $66 PT on Neurocrine Biosciences (NBIX) Following 4Q Results
February 15, 2017 5:56 AM ESTBaird analyst Brian Skorney reiterates Outperform rating and $66 price target on Neurocrine Biosciences (NASDAQ: NBIX), noting the company reported in-line results ahead of Ingrezza launch.
Skorney comments, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly... More
